Johnson & Johnson’s COVID-19 vaccine shows promising response in early trial after one dose – WSYM-TV

Results from early stage trials of Johnson & Johnsons COVID-19 vaccine are promising, showing the one-dose vaccine generates an immune response in nearly all volunteers, with minimal side effects.
The company plans to release more details in a few weeks, and apply for emergency use authorization from the FDA in February.
Researchers say
Phase 1-2 of the vaccine showed either one or two doses of the vaccine generated both antibody and T-cell responses against the coronavirus. The vaccines efficacy,…

Click here to view the original article.